Harbor Capital Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Harbor Capital Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,353	Closed	-$2.64M	–	1248
2026 Q1	$2.64M	Sell	30,353 -10,543	-26%	-$1.03M	0.21%	127
2025 Q4	$4.38M	Buy	40,896 +3,691	+10%	+$392K	0.34%	51
2025 Q3	$3.76M	Sell	37,205 -49,341	-57%	-$4.58M	0.29%	69
2025 Q2	$5.47M	Buy	86,546 +9,249	+12%	+$566K	0.23%	145
2025 Q1	$4.09M	Buy	77,297 +47,045	+156%	+$2.61M	0.19%	175
2024 Q4	$1.69M	Sell	30,252 -11,116	-27%	-$614K	0.07%	340
2024 Q3	$2.17M	Buy	41,368 +6,741	+19%	+$323K	0.09%	288
2024 Q2	$1.42M	Buy	34,627 +11,846	+52%	+$473K	0.11%	272
2024 Q1	$987K	Buy	+22,781	New	+$997K	0.13%	218

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Harbor Capital Advisors's RYTM Position: Q2 2026 in Review

Harbor Capital Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2026, closing a stake of 30,353 shares — an estimated $2.64M sold.

Harbor Capital Advisors first reported a position in RYTM in Q1 2024 and held it in 9 quarters. The position peaked at $5.47M in Q2 2025. 305 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Harbor Capital Advisors reported no remaining Rhythm Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Harbor Capital Advisors sold 30,353 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $2.64M.
Harbor Capital Advisors first reported a position in Rhythm Pharmaceuticals in Q1 2024 and held it in 9 quarters.
Harbor Capital Advisors's Rhythm Pharmaceuticals position peaked at $5.47M in Q2 2025.
305 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.